3510546
Last Update Posted: 2018-04-27
Recruiting status is unknown
All Genders accepted | 18 Years-90 Years |
44 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis
A randomized, placebo-controlled, double-blinded cross-over study evaluating and quantifying the effect of pyridostigmine on muscle strength and symptoms in Myasthenia Gravis (MG)
The study aims to evaluate and quantify the effect of pyridostigmine on symptoms and muscle strength in newly-diagnosed patients and patients on stable medication.
Pyridostigmine treatment is initiated in the vast majority of MG patients. No studies have quantified the effect in a randomized trial, and no studies have examined the potential difference in effect in newly diagnosed patients as compared to patients on stable, antimyasthenic medications.
The study will investigate the effect in two groups
- Newly diagnosed, treatment-naive patients.
- MG patients on stable antimyasthenic medication.
Eligibility
Relevant conditions:
Myasthenia Gravis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov